Previous studies have demonstrated that AML cells expressing FLT3‐ITD are more sensitive to the proteasome inhibitor (PI) bortezomib (Bz) than FLT3 wild‐type cells. The gene discussed is FLT3; the disease is acute myeloid leukemia.